Concepedia

Author

Nicolas Sommer

Duke Medical Center

Also Known As

N. Sommer, Nicolas Sommer, Sommer Nicolas

38

Publications

693

Citations

12

H-Index

23

Concepts

All Affiliations

Duke Medical CenterSarah CannonMayo Clinic in ArizonaTennessee OncologyWashington University in St. Louis
NS

About

Nicolas Sommer is an author at Duke Medical Center specializing in oncology, radiation oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

168

2

Immunology

2

2

97

3

Health Sciences

1

1

15

4

Gastroenterology

1

1

62

5

Molecular Medicine

1

1

41

Nicolas Sommer

×

13

Publications

645

Citations

12

H-Index

YearCitations

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation

David S. Hong, Van K. Morris, Badi El Osta,

Cancer Discovery

2016

213

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)

Herbert I. Hurwitz, Benjamin Tan, James A. Reeves,

The Oncologist

2018

89

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).

Frank A. Sinicrope, Fang‐Shu Ou, Tyler Zemla,

Journal of Clinical Oncology

2019

62

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

Riad Salem, Daneng Li, Nicolas Sommer,

Cancer Medicine

2021

55

Overall survival in patients with glioblastoma before and after bevacizumab approval

Derek R. Johnson, Antonio Omuro, Arliene Ravelo,

Current Medical Research and Opinion

2017

42

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.

Herbert I. Hurwitz, Kanwal Raghav, Howard A. Burris,

Journal of Clinical Oncology

2017

41

Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).

Frank A. Sinicrope, Fang‐Shu Ou, Qian Shi,

Journal of Clinical Oncology

2017

35

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer

Xiaoju Max, Johanna C. Bendell, Herbert I. Hurwitz,

Clinical Cancer Research

2020

29

Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment

Juan Marcos González, Sarika Ogale, Robert Morlock,

Cancer Management and Research

2017

25

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

Johanna C. Bendell, Benjamin Tan, James A. Reeves,

Journal of Clinical Oncology

2016

15

Page 1